口服瘦素增敏剂 ERX1000 联合 semaglutide 在饮食诱导肥胖小鼠中显著增强减重并改善代谢与肌力
In Combination with a GLP-1, ERX Pharmaceuticals' First-in-Class Oral Leptin Sensitizer, ERX1000, Showed Significantly Enhanced Weight Loss, Improved Overall Metabolic Health, and Increased Muscle Strength in Diet-Induced Obese Mice
口服瘦素增敏剂 ERX1000 联合 semaglutide 在饮食诱导肥胖小鼠中使安慰剂校正体重降幅达 36%,高于 semaglutide 单药的 14%。联用还使肌力提高 32%,并改善口服葡萄糖耐量、胰岛素敏感性及瘦体重/脂肪比。ERX1000 单药正在开展 Phase 2a 肥胖临床试验,预计 2027 年下半年完成。
- According to a new study, the combination therapy resulted in a placebo-corrected body weight reduction of 36% over five weeks, compared to 14% for semaglutide alone and 18% for ERX1000
- Combination therapy also improved muscle strength 32% versus the placebo, while increasing the lean mass and lean-to-fat ratio and improving oral glucose tolerance and insulin sensitivity
- As a monotherapy, ERX1000 is currently in a Phase 2a clinical trial after promising results in earlier studies
, /PRNewswire/ -- ERX Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on the discovery and clinical development of innovative treatments for obesity and related diseases, today announced positive results for its orally administered, small-molecule leptin sensitizer, ERX1000, when combined with a GLP-1 receptor agonist semaglutide (SEMA) in diet-induced obese mice.
Dr. Louis Aronne, MD, FTOS, of the Comprehensive Weight Control Center of Weill Cornell Medicine in New York, presented the findings on November 15 at the Obesity Society's ObesityWeek 2026 conference in Washington, D.C. A renowned authority on obesity and its treatment, Dr. Aronne is a member of ERX Pharmaceuticals' board of directors and chair of its scientific advisory board.
The study of diet-induced obese mice found that a therapy combining ERX1000 with semaglutide showed synergistic results, outperforming either monotherapy and the sum of the individual treatment effects. The combined treatment achieved a placebo-corrected body weight reduction of 36% vs. baseline after 35 days of treatment, compared with 18% for ERX1000 alone and 14% for semaglutide alone.
The combination therapy also found improved glucose/insulin sensitivity, reduced fat mass and lipid levels in plasma and in liver, and improved muscle strength and lower intramuscular adipocyte infiltration.
Leptin a Key to Healthy and Sustainable Weight Loss
Leptin is a hormone that mediates body weight by signaling to the brain whether to eat and how much energy to expend. Leptin resistance contributes to obesity by impairing appetite regulation and energy homeostasis. ERX1000 is a novel leptin sensitizer designed to restore leptin responsiveness, thereby suppressing food intake and blocking reduction of energy expenditure with weight loss.
The results of this new study suggest that ERX1000 may help patients taking semaglutide prevent the body from fighting back against weight loss. Semaglutide is the active ingredient in weight-loss and diabetes treatments Wegovy and Ozempic. ERX1000 is currently being investigated in a Phase 2a human clinical trial to assess its safety and tolerability in men and women for the treatment of obesity.
"These findings support leptin sensitization as a potential strategy to enhance the metabolic efficacy of GLP-1 receptor agonist therapy in obesity," Dr. Aronne said. "We believe this therapy could play a role in the fight against obesity moving forward."
"Among other benefits, the combination therapy may mean patients can lower their GLP-1 dose and reduce accompanying side effects," Dr. Aronne added.
Teo Uysal, CEO of ERX Pharmaceuticals, said: "Resistance to the hormone leptin interrupts proper signaling to the brain regarding how much to eat and when to stop. By overcoming leptin resistance, it appears we may be able to restore more normal regulation of appetite and other metabolic benefits."
"Moreover," Uysal added, "with our Phase 2a study currently underway, we are hopeful that additional positive results regarding ERX1000 are yet to come."
In the in vivo study, performed by Physiogenex in France, the combination therapy showed a 39% reduction in food intake compared with 9% for semaglutide alone and 3% for ERX1000 alone. It also showed a greater effect in improving oral glucose tolerance and insulin sensitivity and no decline in body-weight-adjusted energy expenditure.
The combination therapy increased lean mass and lean-to-fat ratio, improved muscle strength in a weight-normalized grip strength test (32%, versus 25% for ERX1000 alone and 8% for semaglutide alone), reduced plasma total cholesterol, and strongly reduced liver-fat and liver-lipids levels (-78% hepatic total cholesterol vs. placebo).
Leptin Sensitization: A New Approach
Leptin sensitization is a new approach to obesity that ERX Pharmaceuticals is developing. People with obesity have sufficient leptin, and resistance to the hormone, rather than the amount of it in the system, is a crucial issue in body-weight regulation leading to an increase in weight. This is similar to insulin resistance in type 2 diabetics. Further, an exaggerated reduction in serum leptin levels that occurs with weight loss may contribute to the plateau phenomenon limiting the amount of weight lost with other treatments.
ERX Pharmaceuticals previously completed two successful Phase 1 clinical trials for ERX1000. The initial trial showed dose-dependent weight loss with no serious nausea or gastrointestinal side effects over a one-month treatment period. The second trial explored a weekly dosing regimen.
The Phase 2a trial in individuals with obesity is expected to be completed by the second half of 2027.
ERX1000 has also received Orphan Drug Designation for the treatment of Prader-Willi syndrome (PWS), a rare genetic disease with no approved drugs available. PWS is characterized by hyperphagia—an extreme insatiable appetite or increased hunger that persists even after a full meal.
The abstract of the study presented at ObesityWeek can be found here.
About ERX Pharmaceuticals Inc.
ERX Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery and clinical development of innovative treatments for obesity and related diseases. ERX's research program is based on a new understanding of the role of the hormone leptin in appetite control and energy expenditure, and the potential for leptin sensitizers to overcome the state of leptin resistance in obesity and related diseases.
ERX Pharmaceuticals was founded in 2014, based on discoveries by researchers at Boston Children's Hospital and Harvard Medical School. The company is based in Cambridge, Massachusetts.
For more information, visit erxpharmaceuticals.com.
MEDIA CONTACT:
PRCG | Haggerty LLC
(212) 683-8100
Lucy O'Brien, [email protected]
Thom Weidlich, [email protected]
SOURCE ERX Pharmaceuticals Inc.

来源:PR Newswire 健康 · prnewswire.com